The Manila Times41m
Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
The Company is planning to announce interim data from its ongoing Halneuron ® Phase 2b chemotherapy induced neuropathic pain ("CINP”) trial in Q4 2025 ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- ...